Belvedere Trading LLC Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Belvedere Trading LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 09, 2024	SELL	$40.88 - $43.27 $32,704 - $34,616	-800 Reduced 25.0%	2,400 $101,000
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $64,864 - $135,808	3,200 New	3,200 $135,000
Q1 2022 Apr 20, 2022	SELL	$23.5 - $35.38 $293,750 - $442,250	-12,500 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$29.21 - $44.64 $365,125 - $558,000	12,500 New	12,500 $316,000
Q3 2021 Oct 19, 2021	SELL	$21.26 - $38.85 $569,768 - $1.04 Million	-26,800 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$12.56 - $29.69 $336,608 - $795,692	26,800 New	26,800 $602,000

270

155M

2.19M

3.92M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Belvedere Trading LLC with notifications on news.